We are currently involved in a number of different venture funds.
Action Potential Venture Capital (APVC)
Action Potential Venture Capital Limited is a strategic venture capital fund of GSK created to invest in companies that are pioneering bioelectronic medicines and their enabling technologies. Launched in 2013, the fund seeks to invest globally with a team based in the US. Learn more about APVC at www.actionpotentialvc.com.
SR One is the venture capital arm of GSK. The group invests globally in emerging life science companies working on innovative science that will significantly improve medical care. SR One, which has experts working in the US and UK, has a portfolio of 30 private and public companies. Since it was founded in 1985, the firm has invested over $680 million in biotech groups.
We know that many great ideas can come from outside of GSK, and collaborating with other companies, organisations and academics is fundamental to our business strategy
Our areas of interest
Find out about the key therapeutic areas we are interested in collaborating on
Find out how we collaborate to discover and develop new vaccines, pharmaceutical and consumer healthcare products
Find out how we work with academic institutions, and what we offer in terms of mutual benefits to research partner